Welcome to LookChem.com Sign In|Join Free

CAS

  • or

16394-71-1

Post Buying Request

16394-71-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

16394-71-1 Usage

General Description

16-ALPHA-METHYLPREGNENOLONE is a synthetic steroid hormone that is chemically similar to naturally occurring hormones in the human body. It is a derivative of pregnenolone and is often used in the production of other steroid hormones, such as progesterone and testosterone. 16-ALPHA-METHYLPREGNENOLONE is known for its anti-inflammatory and immunosuppressive properties and has been studied for its potential use in treating various conditions, including autoimmune diseases and inflammatory disorders. It is also being investigated for its potential neuroprotective and cognitive-enhancing effects. However, its use is still under research, and more studies are needed to fully understand its potential benefits and risks.

Check Digit Verification of cas no

The CAS Registry Mumber 16394-71-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,6,3,9 and 4 respectively; the second part has 2 digits, 7 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 16394-71:
(7*1)+(6*6)+(5*3)+(4*9)+(3*4)+(2*7)+(1*1)=121
121 % 10 = 1
So 16394-71-1 is a valid CAS Registry Number.
InChI:InChI=1/C22H34O2/c1-13-11-19-17-6-5-15-12-16(24)7-9-21(15,3)18(17)8-10-22(19,4)20(13)14(2)23/h5,13,16-20,24H,6-12H2,1-4H3/t13-,16+,17-,18+,19+,20-,21+,22+/m1/s1

16394-71-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 16-α-METHYLPREGNENOLONE

1.2 Other means of identification

Product number -
Other names 3B-HYDROXY-16A-METHYLPREGN-5-EN-20-ONE

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:16394-71-1 SDS

16394-71-1Relevant articles and documents

TRANSFORMED STEROIDS 108. CORRELATION OF OPENING REACTIONS OF 16,17α-CYCLOPROPANO-20-KETOSTEROIDS WITH THE CONFORMATIONS

Kamernitskii, A. V.,Turuta, A. M.,An, Ngo Thi Mai

, p. 669 - 673 (1980)

-

Crystal structure of 3β-acetoxy-17α-hydroxy-16α- methylallopregnan-20-one hemihydrate

Bandhoria, Pankaj,Gupta, Vivek K.,Gupta,Varghese

, p. 427 - 433 (2006)

3β-Acetoxy-17α-hydroxy-16α-methylallopregnan-20-one, C24H38O4?0.5H2O, is an intermediate towards the synthesis of dexamethasone, an important corticosteroid. The compound crystallizes in the monoclinic space group C2 with unit cell parameters: a = 10.665(2) A, b = 7.497(1) A, c = 28.200(4) A, β = 92.74(2)°, Z = 4. The crystal structure has been solved by direct methods and refined to R = 0.0419 for 1579 observed reflections. All rings of the steroid skeleton are trans connected. Rings A, B, and C are all in the chair conformation. Ring D is in envelop conformation. The acetoxy and acetyl substituents are twisted with respect to the average molecular plane of the steroid. The twist along the length of the steroid molecule is negligible [C19-C10???C13-C18 = 2.3°]. In the crystal structure, the water molecule lies on a twofold axis which links the molecules into infinite supramolecular chains through OW-H???O and O- H???OW hydrogen bonds.

Dehydroepiandrosterone (DHEA) congeners for prevention and/or treatment of ulcers

-

, (2008/06/13)

The present invention is related to acute therapeutic uses of dehydroepiandrosterone (DHEA) congeners. These uses include methods for treating or preventing ulcers which comprise administering to a subject either at risk or in need thereof having an ulcer a therapeutic amount of DHEA congener.

Method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue

-

, (2008/06/13)

The present invention is related to a method for enhancing or accelerating re-epithelialization or re-endothelialization of a tissue. Examples of re-epithelialization in which the invention is particularly suited include, but are not limited to, re-epithelialization of (a) skin following surgical wounds, (b) skin abrasions caused by mechanical trauma, caustic agents or burns, (c) cornea following cataract surgery or corneal transplants, (d) mucosal epithelium (respiratory, gastrointestinal, genitourinary, mammary, oral cavity, ocular tissue, liver and kidney) following infection, nonpathological etiologies or drug therapy, (e) skin following grafting and (f) renal tubule following acute tubular necrosis. Examples of re-endothelialization in which the invention is particularly suited include, but are not limited to, re-endothelialization (or regrowth of endothelium) in blood vessels following angioplasty, and the lysis of fibrin clots or lysis or mechanical disruption of thrombi in coronary arteries. In accordance with the present invention, the time to complete re-epithelialization or re-endothelialization is enhanced or accelerated by administering a dehydroepiandrosterone (DHEA) derivative.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 16394-71-1